Viewing data from:

TOREMIFENE CITRATE

ANDA

TOREMIFENE CITRATE | A208813 | RISING PHARMA HOLDINGS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Toremifene Citrate (2023)

Total Spending

$1.2M

Total Claims

1,074

Beneficiaries

173

Avg Cost/Unit

$30.11

Spending Trend

$656K(2019)→$1.4M(2020)→$1.3M(2021)→$1.2M(2022)→$1.2M(2023)

YoY Change:-3.7%

5yr CAGR:-2.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs1 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FERMION OYTOREMIFENE CITRATE

DMF 66521986

OLON SPATOREMIFENE CITRATE

DMF 244072010

OLON SPATOREMIFENE CITRATE

DMF 287702014

MSN LABORATORIES PRIVATE LTDTOREMIFENE CITRATE

DMF 331282018

TAI HENG INDUSTRY CO LTDTOREMIFENE CITRATE

DMF 341422019

ASYMCHEM LABORATORIES TIANJIN CO LTDInactiveTOREMIFENE CITRATE

DMF 306402016

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 22, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 60MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 4, 2018

No patent or exclusivity listings for this strength.